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Abstract
Cerebral venous thrombosis (CVT) is a long-
term debilitating vascular brain disease with
high morbidity and mortality. It may be associ-
ated with rise in D-dimer level. The aim of this
study was to examine this potential associa-
tion and identify the critical D-dimer cut-off
level corresponding to increase the risk of CVT.
This case-control study was conducted on two
groups of patients with and without CVT
attending the Rasool Akram Hospital (Iran)
during 2014 and 2015. D-dimer levels were
measured by the rapid sensitive D-dimer
assay. Data were analyzed by Spearman’s cor-
relation coefficient test, independent-samples
t-test, backward-selection multiple linear
regression and multiple binary logistic regres-
sion analyses. Sensitivity-specificity tests were
used to detect D-dimer cut-off for CVT.
Differences between the D-dimer levels of the
case and control groups were significant
(P<0.001). It showed that each level of
increase in the number of symptoms could
increase the risk of thrombosis occurrence for
about 3.5 times. All symptom types except for
headache were associated with D-dimer level,
while headache has negative association with
D-dimer level. D-dimer cut-off point for CVT
diagnosis was estimated at 350 ng/mg. We con-
cluded that D-dimer serum level significantly
rises in CVT patients. A rounded cut-off point
of 350 ng/mg can be used as a diagnostic crite-
rion for CVT prediction.
Introduction
For a long time cerebral venous thrombosis
(CVT) was known as a rare long-term debilitat-
ing vascular brain disease of high morbidity
and mortality. This disorder presents itself
with a wide range of clinical signs and symp-
toms, like headache, cerebral hemorrhage and
cerebral edema.1 Among its diagnostic chal-
lenges in the emergency department are its
non-specific signs and symptoms.2 In recent
years, the introduction of highly sensitive but
non-invasive techniques such as magnetic res-
onance imaging (MRI), magnetic resonance
venography, and computed tomography venog-
raphy have led to the discovery of more
cases.3,4 However, the difficulties associated
with the use of these techniques have hin-
dered their application as general screening
methods for CVT.5 Hence, a simple, accessible
and accurate method has always been of inter-
est to neurology researchers.
D-dimer is a fibrin degradation product, the
serum level of which begins to rise shortly
after thrombus formation and the process of
clot lysis.6 The measurement of serum D-
dimer levels is nowadays used as a diagnostic
method for non-CVT.7 Although D-dimer has a
similar role in the diagnostic approach toward
Deep Venous Thrombosis (DVT) and pul-
monary thromboembolism it lacks a valid score
for CVT diagnosis. Thus the role of D-dimer is
still a matter of debate in the diagnostic
approach toward suspected cases of CVT.8
One of the most recent statements released
by the American Heart Association and
American Stroke Association recommended the
use of D-dimer as a useful indicator in the
detection of suspected cases of CVT.9
Elsewhere, D-dimer evaluation yielded positive
results in most but not all cases of CVT.10
However, sufficient research has not been con-
ducted on the sensitivity and specificity of D-
dimer in the diagnosis of CVT. Moreover, a con-
clusive D-dimer cut-off point has not been
determined for CVT risk estimation for various
ethnicities such as eastern ones. Considering
the significance of timely diagnosis of CVT and
the uncertainty surrounding the use of D-
dimer in its diagnosis, we conducted this study
to determine the serum levels of D-dimer in
suspected patients attending Rasool Akram
Hospital and in an Iranian population.
Materials and Methods
This case-control study was performed on all
the available records of patients attending the
Rasool Akram Hospital during 2014 and 2015.
The ethics were approved by the Research
Committee of Iran University of Medical
Sciences, in accordance with the Helsinki dec-
laration. 
This study was conducted on two groups of
patients with and without CVT. All patients
attending Rasool Akram Hospital during 2015-
2016 with adequate neuroimaging  (MRI) data
were originally evaluated to diagnose CVT
according to classical neuroimaging signs.
They were divided into two groups of patients
with CVT (cases) and without CVT (controls).
The sample size was determined based on a
pilot study, which included a minimum of 90
patients in both groups (30 cases and 60 con-
trols). The following data were gathered from
all the participants: age, gender, weight,
height, body mass index, cigarette smoking
status, pregnancy, menopause status in
women, intake of oral contraceptive pills
(OCPs) in women, and their dosage if taken. 
The participants’ clinical signs and symp-
toms were assessed as well: isolated headache;
headache and papilledema; and encephalic
signs (seizure, focal weakness, consciousness,
etc.). Relevant CVT risk factors [pregnancy,
menopause status, OCPs use, factor V Leiden,
Body Mass Index (BMI), smoking] were
assessed and identified. Before starting any
treatment or medications, including anticoag-
ulant drugs in the case group, all the partici-
pants had blood tests conducted. Their D-
dimer levels were measured by the rapid sen-
sitive D-dimer assay and the results were
reported.Statistical analysis
Data were analyzed in the SPSS program
(IBM Corp. Released 2011. IBM SPSS Statistics
for Windows, Version 20.0. Armonk, NY, USA).
Descriptive statistics (mean and median)
were calculated for both groups. Associations
between variables were assessed using
Spearman’s correlation coefficient, independ-
ent-samples t-test, backward-selection multi-
ple linear regression, and multiple binary
logistic regression analyses. The critical D-
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dimer level was estimated by sensitivity analy-
sis. The level of significance was predeter-
mined as 0.05.
Results
In the case group there were 16 males and
13 females, with a mean age of 41.0±15.0
years (36.3±13.4 in females; 44.8±15.6 in
males). In order to the site of thrombosis,
there was 17 cases of transverse sinus (58%),
9 in sagittal sinus (31%), 2 in vein of Galen
(6.9%) and one in vein of Labbe (3.5%). In the
control group (patients clear of thrombosis
diagnosis), there were 35 males and 24
females, with a mean age of 42.2±13.8 years
(39.4±11.3 in females; 44.0±45.2 in males).
The mean D-dimer level in the case group
was 2450.6±753.5 ng/mg (range: 135 to 3459),
2268.8±861.5 ng/mg, and 2598.4±643 ng/mg,
respectively in 29 patients, 13 females and 16
males. There was only one patient with a D-
Dimer level of 135 ng/mg, and the rest of cases
had D-Dimer levels above 1000 ng/mg. None of
the females was smokers, while 5 males
(31.3%) were smokers. Of the female cases,
only 3 (23.1%) were taking OCPs. Of them, 1
(7.7%) was pregnant, 2 others (15.4%) were in
their first or second postpartum weeks, and 3
(23.1%) were menopausal. The mean BMI was
5.2±2.6 kg/m2 (25.4±2.4 in females; 25.1±2.8
in males). The factor V Leiden was positive in
1 woman (7.7%) and 3 men (18.8%). Of the 29
cases, 55.2%, 41.4%, and 3.4% had respectively
1, 2, and 3 symptoms. Headache, hemiparesis,
and seizure were reported by 48.3%, 27.6%,
and 58.6% of the cases, respectively. Other
symptoms (confusion, visual problems, ataxia,
etc.) were reported by 10.3% of the cases. In
the control group, D-dimer levels were
27.7±7.2 (range: 12 to 43), 29.8±6.6, and
26.3±7.3, respectively in the controls i.e. 24
females, and 35 males. Twelve males (34.3%)
were smokers. There were no female smokers.
Of the female controls, only 1 (4.2%) was preg-
nant. The mean BMI of control group was
24.7±2.0 ng/mg (24.9±1.8 in females; 24.6±2.1
in males). Among the 59 controls, 79.7% and
20.3% had respectively 1 and 2 symptoms (i.e.,
only headache and seizure). Headache, hemi-
paresis, and seizure were reported by 100%,
0.0%, and 20.3% of the controls, respectively.
Other symptoms (confusion, visual problems,
ataxia, etc.) were not reported by any of the
control group participants. Subgroup analysesCase (cerebral venous thrombosis-positive)
The backward-selection multiple linear
regression on the case group data (n=29)
showed that of all the above mentioned vari-
ables (excluding symptom types), only age
(beta=0.472; P=0.015) significantly predicted
D-dimer levels (all other variables were
insignificant). According to the analyses per-
formed on the case group data (n=29), among
the symptoms, headache (beta=-0.438;
P=0.011) negatively predicted D-dimer levels.
The symptoms hemiparesis, and seizure were
not associated with D-dimer levels. However,
other symptoms (confusion, ataxia, visual
problems) were collectively associated with
D-dimer levels (beta=0.352; P=0.036).Control (cerebral venous thrombosis-negative) 
The backward-selection multiple linear
regression on the control group data (n=59)
showed that of all the above-mentioned vari-
ables (symptom types excluded), only age
(beta=0.303; P=0.018) and female gender
(beta=0.293; P=0.022) positively predicted D-
dimer levels in the controls, and all other vari-
ables were insignificant. None of the symp-
toms was associated with D-dimer levels in
the control group.Analysis of complete data
Based on the t-test results, the difference
between the D-dimer level of the case and
control groups was significant (P<0.001). A
regression analysis was performed over the
whole data (n=88). The variables included all
the items in above-mentioned regressions as
well as the number of symptoms present in
patients, but excluding the types of symp-
toms. Only age (beta=0.086; P=0.022) and
thrombosis (beta=0.940; P=0.000000) were
predictors of D-dimer levels. A separate analy-
sis was performed on symptom types only.
According to the linear regression, all symp-
tom types except headache were positively
associated with D-dimer levels, while
headache was negatively associated with D-
dimer levels (Table 1). Spearman’s coefficient
showed excellent correlations between
thrombosis occurrence, D-dimer levels, and
symptoms (Table 2). The multiple binary
logistic regression analysis was used to
assess the association of all variables except
D-dimer and symptom types with thrombosis
occurrence. It showed that each level of
increase in the number of symptoms could
increase the risk of thrombosis occurrence
for about 3.5 times [odds ratio (OR)=3.4,
Table 3].D-dimer’s cut-off value for cere-bral venous thrombosis prediction
The rounded critical D-dimer cut-off point
was estimated to be 350 ng/mg (rounded from
342.5 ng/mg), above which, patients are at a
much increased risk of thrombosis (receiver-
operator curve’s P<0.0001).
Discussion
D-dimer increases in the serum following
fibrinolysis of blood clots.10 Assessment of its
serum levels can confirm the process of clot
formation and fibrinolysis. Based on our
results the serum level of D-dimer was signif-
icantly higher in CVT patients than in the
control group. Furthermore, all the CVT signs
were associated with the D-dimer level,
except for headache. An increase in the num-
ber of symptoms was associated with an
increased risk of thrombosis. Age and the
female gender were positively associated
with the D-dimer level.
The D-dimer level was significantly differ-
ent in the CVT group when compared to the
control group in 350 ng/mg cut-off level.
Other studies have confirmed elevated levels
of serum D-dimer following CVT, but critical
cut-off value was 500 ng/mg in most stud-
ies,11,12 probably due to the prevalence of
other CVT predisposing factors in different
populations. Lalive and colleagues assessed
the D-dimer level for the purpose of CVT
diagnosis, and found the sensitivity and
specificity to be 83% and 90%.13 Dentali and
colleagues studied the diagnostic value of D-
dimer serum level in CVT. The weighted
mean sensitivity of D-dimer was estimated at
93.9% (95% CI 87.5-97.1) and its weighted
mean specificity was estimated at 89.7%
(95% CI 86.5-92.2).14 So, it seems that
decreasing D-dimer cut-off level may
increase the diagnostic value of this test in
CVT. In this study, the female gender and age
were D-dimer level determinants in patients
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Table 1. Linear regression test of D-dimer serum level in patients with and without cere-
bral venous thrombosis.
Symptom                                       Beta                         t                                   P
Headache                                                    -0.452                           -4.622                                     0.000
Hemiparesis                                                0.251                            2.772                                      0.007
Seizure                                                         0.205                            2.758                                      0.007










clear of CVT, while age alone might predict D-
dimer levels among CVT patients (and in the
whole sample of both CVT patients and those
without CVT). Other studies showed that, in
middle-aged women CVT was three times
more common among women than in men.3
This difference is due to the difference in
risk factors (such as OCPs, pregnancy,
menopausal age, hormone replacement ther-
apy).15 One fourth of the female population of
this sample took contraceptives, and about
the same number were menopausal. Studies
have also shown that the incidence of CVT at
older age is associated with the presentation
of more severe and fewer minor symptoms;
more often it presents with decreased con-
sciousness. Previously, it has been recog-
nized that the D-dimer level is directly asso-
ciated with the size of the thrombus. It
appears that older age is associated with an
increased size of thrombus, which in turn
creates more severe symptoms and elevates
the D-dimer level.8 Moreover, morphological
changes (cortical atrophy, hippocampus, and
subcortical tissue changes) and biochemical
changes of the brain (reduced cholinergic
and dopaminergic activity) are associated
with increase in age.16 Simultaneously, age-
related changes in cerebral blood flow make
the brain tissue more vulnerable,16 leading to
more severe symptoms and CVT complica-
tions compared to younger CVT.
Usually, the absence of headache in CVT
indicates parenchymal damages and more
severe symptoms such as seizures and motor
weakness.17 A previous study showed that D-
dimers have a high negative predictive value
in patients with isolated headache for
excluding CVT,18 in our study, apart from
headache, all the symptoms were associated
with a rise in D-dimer level. This lack of
association may perhaps be attributed to the
size of the thrombus in CVT, which results in
all the symptoms but headache. However, fur-
ther more controlled studies are needed to
evaluate this.
Conclusions
CVT may occur more in patients with a high-
er number of symptoms. No strong association
was found between CVT risk and items such as
age, smoking, or BMI. D-dimer level may be
higher in older patients and those experienc-
ing either hemiparesis, seizure, or a combina-
tion of confusion, ataxia, and visual problems,
but not in those with headache (which showed
a negative association and needs future
research). D-dimer serum level significantly
rises in CVT patients compared to the control
group. A rounded cut-off point of 350 ng/mg
can be used as a diagnostic criterion for CVT
prediction.
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Table 3. Binary logistic regression test of factors associated with cerebral venous throm-
bosis.
Variable                                     P                              OR                          95% CI for OR
Male sex                                              0.859                                  0.908                                      0.314, 2.632
Age                                                        0.491                                  0.987                                      0.950, 1.025
Number of symptoms                      0.012                                  3.399                                      1.305, 8.849
Smoking                                               0.678                                  1.346                                      0.331, 5.478
Body mass index                                0.219                                  1.157                                      0.917, 1.460
OR, odds ratio; CI, confidence interval.
Table 2. Spearman correlation coefficient test of D-dimer serum level in patients with and without cerebral venous thrombosis.
                                                     Sex   Age         D-        Symptom    Headache Hemiparesis   Seizure    Other     Smoking         Oral       Menopause         Pregnancy  Body 
                                                             dimer  number                                                                      symptoms              contraceptive    mass
                                                                                                                                                                                                         use             index
Age                                               Rho     0.207                                                                                                                                                                                                                                                                                                                 
                                                      P          0.053                                                                                                                                                                                                                                                                                                                 
D-dimer                                     Rho    -0.117  0.125                                                                                                                                                                                                                                                                                                    
                                                      P          0.278   0.246                                                                                                                                                                                                                                                                                                    
Symptom number                  Rho    -0.069  -0.038        0.266                                                                                                                                                                                                                                                                                
                                                      P          0.524   0.724         0.012                                                                                                                                                                                                                                                                                
Headache                                  Rho    -0.019  -0.266        -0.586             0.021                                                                                                                                                                                                                                                        
                                                      P          0.862   0.012         0.000              0.850                                                                                                                                                                                                                                                        
Hemiparesis                            Rho     0.029   0.211         0.399              0.061                  -0.592                                                                                                                                                                                                                          
                                                      P          0.788   0.048         0.000              0.575                   0.000                                                                                                                                                                                                                           
Seizure                                       Rho    -0.040  0.045         0.354              0.776                  -0.325                  -0.054                                                                                                                                                                                            
                                                      P          0.715   0.679         0.001              0.000                   0.002                   0.620                                                                                                                                                                                             
Other symptoms                    Rho    -0.094  -0.005        0.307              0.332                  -0.248                  -0.059                  0.135                                                                                                                                                                
                                                      P          0.385   0.964         0.004              0.002                   0.020                   0.582                  0.211                                                                                                                                                                
Smoking                                     Rho     0.428   0.415         0.068             -0.112                 -0.054                  -0.074                 -0.070           0.084                                                                                                                                          
                                                      P          0.000   0.000         0.527              0.297                   0.617                   0.493                  0.519            0.436                                                                                                                                          
Oral contraceptive use        Rho     0.969   0.260         0.188             -0.018                 -0.074                   0.041                  0.108           -0.190             0.443                                                                                                                  
                                                      P          0.000   0.173         0.327              0.928                   0.702                   0.831                  0.576            0.323              0.016                                                                                                                  
Menopause                              Rho    -0.744  -0.522        -0.281             -0.026                  0.247                   -0.414                  0.110            0.017             -0.340                 -0.661                                                                                    
                                                      P          0.000   0.004         0.140              0.895                   0.197                   0.026                  0.571            0.931              0.071                  0.000                                                                                     
Pregnancy                                  Rho    -0.288  -0.218        0.148              0.060                  -0.019                  -0.078                  0.141           -0.046             -0.123                 -0.434                   0.506                                                       
                                                      P          0.006   0.042         0.169              0.576                   0.858                   0.472                  0.189            0.670              0.252                  0.019                   0.005                                 .                      
Body mass index                    Rho    -0.038  0.262         0.121             -0.051                 -0.219                   0.156                  0.050           -0.051             0.129                 -0.122                  -0.080                           0.245                 
                                                      P          0.725   0.014         0.260              0.639                   0.040                   0.147                  0.644            0.640              0.230                  0.528                   0.678                            0.022                .
Thrombosis                              Rho    -0.040  -0.023        0.815              0.262                  -0.647                   0.451                  0.383            0.268              0.000                                                                                      0.141            0.084
                                                      P          0.715   0.829         0.000              0.014                   0.000                   0.000                  0.000            0.012              0.995                                                                                      0.189            0.437
Factor V Leiden                      Rho     0.159  -0.323        0.000              0.219                   0.014                   -0.023                  0.133            0.192             -0.203                 0.134                   -0.052                          -0.136          -0.282
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